A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease (AMBAR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01561053 |
|
Recruitment Status :
Completed
First Posted : March 22, 2012
Results First Posted : July 31, 2019
Last Update Posted : July 31, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer's Disease | Biological: Albumin 5% Biological: Albumin 20% Biological: Immunoglobulin | Phase 2 Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 347 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate Alzheimer's Disease |
| Actual Study Start Date : | April 19, 2012 |
| Actual Primary Completion Date : | March 6, 2018 |
| Actual Study Completion Date : | March 6, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: High Albumin + Immunoglobulin
Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
|
Biological: Albumin 5%
Therapeutic plasma exchange with human albumin 5%
Other Names:
Biological: Albumin 20% Low volume plasma exchange with human albumin 5%
Other Names:
Biological: Immunoglobulin Intravenous human immunoglobulin 5%
Other Name: Flebogamma® 5% DIF |
|
Experimental: Low Albumin + Immunoglobulin
Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
|
Biological: Albumin 5%
Therapeutic plasma exchange with human albumin 5%
Other Names:
Biological: Albumin 20% Low volume plasma exchange with human albumin 5%
Other Names:
Biological: Immunoglobulin Intravenous human immunoglobulin 5%
Other Name: Flebogamma® 5% DIF |
|
Experimental: Low Albumin
Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period)
|
Biological: Albumin 5%
Therapeutic plasma exchange with human albumin 5%
Other Names:
Biological: Albumin 20% Low volume plasma exchange with human albumin 5%
Other Names:
|
|
No Intervention: Control (sham) group
Simulated plasma exchange procedure
|
- Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score (Changes From Baseline to 14 Months) [ Time Frame: Baseline and 14 months ]
ADAS-Cog total score as a change from baseline to 14 months
The ADAS-Cog Scale is a questionnaire that assesses cognitive performance in 12 different domains. The domains are: word recall, commands, constructional praxis, delayed word-recall task, naming objects/figures, ideational praxis, orientation, word recognition, remembering test instructions, comprehension, word finding difficulty, and spoken language ability. The total score ranges from 0-80 where a higher score indicates more cognitive impairment.
- Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score (Changes From Baseline to 14 Months) [ Time Frame: Baseline and 14 Months ]
ADCS-ADL total score as a change from baseline to 14 months
The ADCS-ADL comprises 23 questions covering a wide array of activities of daily living. Many of the activities begin with an assessment of whether that activity is relevant and then, if yes, follow with an assessment of the difficulty. The total score over all activities ranges from 0-78 where a higher score indicates more autonomy (better outcome).
- ADAS-Cog Total Score (Changes From Baseline to 14 Months) in Patients With Baseline MMSE:22-26 [ Time Frame: Baseline and 14 months ]
ADAS-Cog total score as a change from baseline to 14 months in patients with baseline Mini-Mental State Examination (MMSE):22-26
The ADAS-Cog Scale is a questionnaire that assesses cognitive performance in 12 different domains. The domains are: word recall, commands, constructional praxis, delayed word-recall task, naming objects/figures, ideational praxis, orientation, word recognition, remembering test instructions, comprehension, word finding difficulty, and spoken language ability. The total score ranges from 0-80 where a higher score indicates more cognitive impairment.
- ADCS-ADL Total Score (Changes From Baseline to 14 Months) in Patients With Baseline MMSE:22-26 [ Time Frame: Baseline and 14 months ]
ADCS-ADL total score as a change from baseline to 14 months in patients with baseline Mini-Mental State Examination (MMSE):22-26
The ADCS-ADL comprises 23 questions covering a wide array of activities of daily living. Many of the activities begin with an assessment of whether that activity is relevant and then, if yes, follow with an assessment of the difficulty. The total score over all activities ranges from 0-78 where a higher score indicates more autonomy (better outcome).
- ADAS-Cog Total Score (Changes From Baseline to 14 Months) in Patients With Baseline MMSE:18-21 [ Time Frame: Baseline and 14 months ]
ADAS-Cog score as a change from baseline to 14 months in patients with baseline Mini-Mental State Examination (MMSE):18-21
The ADAS-Cog Scale is a questionnaire that assesses cognitive performance in 12 different domains. The domains are: word recall, commands, constructional praxis, delayed word-recall task, naming objects/figures, ideational praxis, orientation, word recognition, remembering test instructions, comprehension, word finding difficulty, and spoken language ability. The total score ranges from 0-80 where a higher score indicates more cognitive impairment
- ADCS-ADL Total Score (Changes From Baseline to 14 Months) in Patients With Baseline MMSE:18-21 [ Time Frame: Baseline and 14 months ]
ADCS-ADL total score as a change from baseline to 14 months in patients with baseline Mini-Mental State Examination (MMSE):18-21
The ADCS-ADL comprises 23 questions covering a wide array of activities of daily living. Many of the activities begin with an assessment of whether that activity is relevant and then, if yes, follow with an assessment of the difficulty. The total score over all activities ranges from 0-78 where a higher score indicates more autonomy (better outcome).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 55 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
- Males or females between 55-85 years of age at the time of signing of the informed consent document.
- A diagnosis of Alzheimer's disease (NINCDS-ADRDA criterion), and mini-mental status examination (MMSE) score between >/=18 and </=26.
- Current stable treatment with acetylcholine esterase inhibitors (AChEIs) and/or memantine for the previous three months.
- The patient and a close relative or the legal representative must read the patient information sheet, agree to participation in the trial, and then sign the informed consent document (the patient personally and the close relative/legal representative).
- The patient must be able to follow the study protocol, receive the treatment in the established time period, and continue during the follow-up interval.
- A brain computed axial tomography (CAT) or magnetic resonance imaging (MRI) study, obtained in the 12 months prior to recruitment, showing the absence of cerebrovascular disease, should be available. Nevertheless, it is mandatory to use the MRI obtained during the screening period to rule out any cerebrovascular disease.
- A stable care taker must be available, and must attend the patient study visits.
Main Exclusion Criteria:
-
Any contraindication for plasma exchange due to behavioral disorders or abnormal coagulation parameters, such as for example:
- Hypocalcemia (Ca++ < 8.7 mg/dL)
- Thrombocytopenia (<100,000/µL)
- Fibrinogen <1.5 g/L
- Prothrombin time (Quick) p<60% versus control (international normalized ratio (INR) >1.5)
- Beta-blocker treatment and bradycardia <55/min
- Treatment with angiotension-converting enzyme inhibitors (ACEIs) (increased risk of allergic reactions)
- Hemoglobin < 10 g/dL
- Difficult venous access precluding plasma exchange.
- A history of frequent adverse reactions (serious or otherwise) to blood products.
- Hypersensitivity to albumin or allergies to any of the components of Albutein.
- History of immunoglobulin A (IgA) deficiency.
- Known allergies to Flebogamma DIF components such as sorbitol.
- History of thromboembolic complications of intravenous immunoglobulins.
- Plasma creatinine > 2 mg/dl.
- Uncontrolled high blood pressure (systolic blood pressure of 160 mmHg or higher and/or diastolic blood pressure of 100 mmHg or higher despite treatment during the last 3 months).
- Liver cirrhosis or any liver problem with glutamic pyruvic transaminase (GPT) > 2.5 x upper limit of normal (ULN), or bilirubin > 2 mg/dL.
- Heart diseases, as evidenced by myocardial infarction, severe or unstable angina, or heart failure (New York Association Class II, III or IV) in the past 12 months.
- Participation in other clinical trials, or the receipt of any other investigational drug in the three months prior to the start of the study.
- Any condition complicating adherence to the study protocol (illness with less than one year of expected survival, known drug or alcohol abuse, etc.).
- Pregnant or nursing women or women not using effective contraceptive methods for at least one month after plasma exchange.
- Fewer than six years of education (exclusion criteria under medical criterion).
- Less than three months with stable treatment for behavioral disorders or insomnia.
- Patients being treated with anticoagulants or antiplatelet therapy (antiaggregants) should not be recruited in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01561053
Show 40 study locations
| Principal Investigator: | Merce Boada Rovira, MD, PhD | Fundació ACE. Barcelona. Spain | |
| Study Chair: | Antonio Páez, MD | Instituto Grifols, S.A. | |
| Study Director: | Laura Núñez, BSc | Instituto Grifols, S.A. |
Documents provided by Grifols Biologicals, LLC ( Instituto Grifols, S.A. ):
| Responsible Party: | Instituto Grifols, S.A. |
| ClinicalTrials.gov Identifier: | NCT01561053 |
| Other Study ID Numbers: |
IG1002 |
| First Posted: | March 22, 2012 Key Record Dates |
| Results First Posted: | July 31, 2019 |
| Last Update Posted: | July 31, 2019 |
| Last Verified: | July 2019 |
|
Alzheimer's disease Amyloid Beta (AB) peptide Albumin Intravenous immunoglobulin IVIG |
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases |
Neurocognitive Disorders Mental Disorders Immunoglobulins Immunoglobulins, Intravenous Antibodies Immunologic Factors Physiological Effects of Drugs |